



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2

**CERTIFICATE OF MAILING**

I hereby certify under 37 C.F.R. 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Label No. EV493187780 US with sufficient postage on the date indicated below and in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

[ X ] If checked, two copies of this correspondence are enclosed.

Dawn M. Janelle

Signature

Date of Deposit: June 10, 2005

Dawn M. Janelle

Printed name of person mailing correspondence

Applicant:	DONG, Zheng Xin et al.	Art Unit:	Unknown
Serial No.:	10/522,398	Examiner:	Unknown
Filed:	January 21, 2005		
Title:	GHRELIN ANALOGS		

**INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO  
CHARGE DEPOSIT ACCOUNT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[ ] under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)

[ X ] under 37 CFR 1.97(b), or  
(Whichever occurs last of the following: within three months of filing national application; within three months of date of entry of the national stage in international application; before the mailing date of first office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination)

[ ] under 37 CFR 1.97(c) together with either:

[ ] a Statement under 37 CFR 1.97(e), as checked below, or

[ ] a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[ ] under 37 CFR 1.97(d) together with:

[ ] a Statement under 37 CFR 1.97(e), as checked below, and

[ ] a Petition under 37 CFR 1.97(d)(2), and

[ ] a \$130.00 petition fee set forth in 37 CFR 1.17(i).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

[ ] Applicant requests that the attached IDS and cited reference(s) [ ] be placed in the application filewrapper.  
(Filed after payment of issue fee)

[ X ] Some of the listed references were cited in a European Search Report in a counterpart European application or cited in a communication from a foreign patent office in a counterpart foreign application.

Enclosed herewith is form PTO/1449 (1 page; reproduced form), with a copy of each reference noted thereon.

Enclosed herewith is form PTO/1449 (1 page; reproduced form), with a copy of selected references noted thereon. As per the change to 37 CFR 1.98(a)(2) published in the September 21, 2004 Federal Register and effective as of October 21, 2004, in which the requirement for a copy of each U.S. Patent or U.S. Patent application publication listed in an IDS has been eliminated regardless of the filing date of the application (unless required by the Office), copies of any United States Patent or Patent Publications are not enclosed.

Copies of the reference(s) noted on the enclosed form PTO/1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)). Applicants request that copies of art in U.S. Application Serial No. [ ] cited on the enclosed PTO/1449 form be transferred to the present U.S. Application Serial No. [ ].

Concise Explanation Requirement (non-English references):

The "concise explanation" requirement for reference(s) [B ] under 37 CFR 1.98(a)(3) is satisfied by:

the explanation provided on the attached sheet.

the explanation provided in the Specification.

submission of the enclosed International Search Report.

the enclosed English language document reasonably believed to be an English equivalent.

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO/SB/08B appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Statement Under 37 CFR 1.97(e):

Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Method of payment:

A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.

No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.

The Commissioner is hereby authorized to charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.


Respectfully submitted,  
BIOMEASURE, INCORPORATED

Dated: June 10, 2005

By Pamela C Ball  
Pamela C. Ball, Agent for Applicant(s)  
Registration No.: 53,963

27 Maple Street  
Milford, Massachusetts 01757  
Phone: (508)478-0144  
Facsimile: (508) 473-3531

**BEST AVAILABLE COPY**



EX-107  
1449 REPRODUCED  
INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION  
(Use several sheets if necessary)

ATTORNEY DOCKET NO.  
113P2/PCT3/US

APPLICATION NO.  
10/522,398

APPLICANT  
DONG, Zheng Xin

FILING DATE  
January 21, 2005

GROUP/EXAMINER  
Unknown/Unknown

U. S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
-------------------------------	--	-----------------	------	------	-------	---------------	----------------------------------

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES      NO
	A	97/21730	06/19/97	WIPO			
	B	01/07475	02/01/01	WIPO			X
	C	01/92292	12/06/01	WIPO			
	D	02/08250	01/31/02	WIPO			
	E	1 197 496	04/17/02	EP			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	F	ASAKAWA, A. et al., "Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin," <i>Gastroenterology</i> , 2001, 120:337-345.
	G	BEDNAREK, M. et al., "Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a," <i>J. Med. Chem.</i> , 2000, 43:4370-4376.
	H	BOWERS, C. Y., "Unnatural growth hormone-releasing peptide begets natural ghrelin," <i>J. Clinical Endo. &amp; Metab.</i> , 2001, 86:1464-1469.
	I	CUMMINGS, D. et al., "Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery," <i>N. Engl. J. Med.</i> , 2002, 346:1623-1630.
	J	DIEGUEZ, C. et al., "Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation," <i>European J. Endocrinology</i> , 2000, 142:413-417.
	K	FLIER, J. et al., "The stomach speaks - ghrelin and weight regulation," <i>N. Engl. J. Med.</i> , 2002, 346:1662-1663.
	L	KAIYA, H. et al., "Bullfrog ghrelin is modified by n-octanoic acid at its third threonine residue," <i>J. Biol. Chem.</i> , 2001, 276:40441-40448.
	M	KOJIMA, M. et al., "Ghrelin is a growth-hormone-releasing acylated peptide from stomach," <i>Nature</i> , 1999, 402:656-660.
	N	MATSUMOTO, M. et al., "Structure-activity relationships of ghrelin endogenous growth hormone secretagogue," <i>Peptide Science</i> , 2000, p101-104
	O	MATSUMOTO, M. et al., "Structural similarity of ghrelin derivatives to peptidyl growth hormone secretagogues," <i>Biochem. Biophys. Res. Comm.</i> , 2001, 284:655-659.
	P	PAPOTTI, M. et al., "Growth hormone secretagogue binding sites in peripheral human tissues," <i>J. Clin. Endo. &amp; Metab.</i> , 2000, 85:3803
	Q	PEINO, R. et al., "Ghrelin-induced growth hormone secretion in humans," <i>European J. Endocrinolgy</i> , 2000, 143:R11-R14.
	R	SVENSSON, J., "Growth hormone secretagogues as therapeutic agents," <i>Growth Hormone &amp; IGF Res.</i> , 1999, 9:107-109.
	S	TAKAYA, K. et al., "Ghrelin strongly stimulates growth hormone (GH) release in humans," <i>J. Clinical Endo. &amp; Metab.</i> , 2000, 85:4908-4911.
	T	TOLLE, V. et al., "In vivo and in vitro effects of ghrelin/motilin-related peptide on growth hormone secretion in the rat," <i>Neuroendocrinology</i> , 2001, 73:54-61.
	U	WISSE, B. et al., "Reversal of cancer anorexia by blockade of central melanocortin receptors in rat," <i>Endocrinology</i> , 2001, 142:3292-3301.
	V	WREN, A. et al., "The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion," <i>Endocrinology</i> , 2000, 141:4325-4328.
	W	WREN, A. et al., "Ghrelin causes hyperphagia and obesity in rats," <i>Diabetes</i> , 2001, 50:2540-2547.

EXAMINER

DATE CONSIDERED

BEST AVAILABLE COPY